Phialogics
Innovative protein‑derived multi‑specific antibodies for autoimmune disease treatment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative protein‑derived multi‑specific antibodies for autoimmune disease treatment.
ImmunologyAutoimmune Diseases
Technology Platform
Phialogics’ platform converts native proteins into engineered bi‑functional, bi‑specific and multi‑specific antibodies that modulate immune pathways.
Opportunities
The platform can be applied across a broad range of autoimmune indications, offering a differentiated approach to immune‑balance resetting.
Risk Factors
Execution risk in advancing multi‑specific biologics through preclinical to clinical stages and securing funding.
Competitive Landscape
Few companies focus on native‑protein‑derived multi‑specific antibodies, differentiating Phialogics from traditional monoclonal antibody developers.